According to the latest quarterly results, Deep Health AI India reported a consolidated net loss of ₹4.51 crore in Q4 FY26, marking a significant reversal from the net profit of ₹0.35 crore recorded in the corresponding quarter of the previous year. The company's sales performance also declined substantially, falling 44.44% to ₹0.25 crore in Q4 FY26 compared to ₹0.45 crore in Q4 FY25. The operational profit margin (OPM) for the quarter stood at 20%. As per the latest financial data, Q4 revenue stood at ₹0.50 crore, reflecting a quarter-on-quarter decrease of 85.07% from ₹3.35 crore in the previous quarter, though showing a year-on-year decline of 0.00%.
Despite the challenging quarterly performance, Deep Health AI India demonstrated strong annual growth momentum. The company achieved a consolidated net profit of ₹113.39 lakh for the full year ended March 2026, representing a 28.41% increase from ₹87.65 lakh in the previous financial year. Annual sales performance was particularly robust, rising 237.30% to ₹425.00 lakh in FY26 compared to ₹1.26 crore in FY25, indicating significant business expansion during the year. The latest results show full-year revenue growth of 237.30% to ₹425.00 lakh compared to the previous year, with other income contributing ₹424.02 lakh to the total revenue.
The company's annual results include significant exceptional items related to strategic acquisitions and operational challenges. An exceptional item of ₹577.81 lakh was recognized in standalone accounts, primarily due to the acquisition of Oasis Ceramics Pvt. Ltd. under the Insolvency and Bankruptcy Code. The company faced delays in payment timelines, leading to the invocation of a bank guarantee amounting to ₹3.21 crore and the recognition of an exceptional loss based on management's assessment. Additionally, during the year, Deep Health AI India raised ₹39.97 crore through a Rights Issue, with ₹2.5 crore utilized towards stated objects and ₹37.47 crore deployed for investments through recognized stock exchanges, representing a deviation ratified by shareholders in January 2026. The company also disposed of its investment in Hemonc Pharma Private Limited on March 28, 2026.
According to the financial data reported by Business Standard, the company's profit before depreciation and tax (PBDT) for Q4 FY26 was ₹0.23 crore, down 41% from ₹0.39 crore in the previous quarter. For the full year, PBDT improved significantly to ₹7.38 crore from ₹1.13 crore in the previous year, representing a 553% increase. The latest quarterly results show PBDT at ₹3.65 crore, reflecting a quarter-on-quarter increase of 7.99% from ₹3.38 crore in the previous quarter, with a year-on-year growth of 3,955.56%. Profit before tax (PBT) for Q4 FY26 stood at ₹0.23 crore, declining 41% from ₹0.39 crore in Q4 FY25, while full-year PBT reached ₹7.37 crore compared to ₹1.11 crore in the previous year.
The mixed financial results reflect the company's operational challenges in the fourth quarter while highlighting its strong annual performance trajectory. The significant decline in quarterly sales and profitability compared to the previous year's corresponding quarter indicates potential market headwinds or operational adjustments during the final quarter of FY26. The company's strategic focus on acquisitions and investment deployment, combined with the disposal of non-core investments, positions it for potential future growth opportunities. The Board of Directors approved the appointment of M/s. Valawat & Associates Chartered Accountants as the Internal Auditor for financial year 2026-2027, demonstrating commitment to robust financial governance. The company's stock performance shows a 52-week high of ₹21.00 achieved on November 21, 2025, and a 52-week low of ₹6.00 recorded on April 6, 2026.
